Liu Xia, Deputy Director of Breast Tumor Center, Masters Degree in Clinical Medicine, Deputy Chief Physician of Surgical Oncology, Intermediate in General Surgery and Plastic Surgery. Started working in August 2006, now serving as registered physician of drug grant program of the China Cancer Foundation, China Charity Federation and China Primary Health Care Foundation. Awarded "Outstanding Individual" by Hainan Cancer Hospital in 2017; "Advanced Team" by his department in 2017; "Individual with the Most Cooperative Spirit" in 2019; "Outstanding Employee" by the First Investment Group System in 2019, and "Department with the Most Cooperative Spirit" to his department; 2020 "The Most Beautiful Physician" of Hainan Cancer Hospital; 2018 CSCO Breast Cancer Diagnosis and Treatment South Tour and Standardized Treatment Competition Award of Excellence; Award of the best style of South China Regional Competition, 2019 Roche Breast Cancer Standardized Diagnosis and Treatment Competition.

Diagnosis and treatment of benign and malignant breast tumors, full management of breast cancer treatment, minimally invasive rotational excision under molybdenum 3D localization, breast-conserving intra-operative radiotherapy and mammoplasty related surgeries.

Breast tumor, GCP drug clinical trials.

Vice Chairman of the Breast Cancer Youth Committee of Hainan Anti-Cancer Association  
Secretary General of Breast Tumor Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the Second Committee of Breast Surgeons Branch of Hainan Provincial Medical Doctor Association 
Standing member of Breast Tumor Plastic Surgery Professional Committee of Hainan Cancer Prevention and Treatment Association 
Standing member of the First Session of the Cancer Health Professional Committee of Hainan Anti-Cancer Association 
Member of the First Session of the Tumor Interventional Professional Committee of Hainan Cancer Prevention and Treatment Association 
Member of the Second Council of Chinese Anti-Cancer Association 
Member of Expert Committee of Medical Quality Control Center of Breast Surgery Specialty in Hainan Province (2023.06-2024.12)

I. "Outstanding Individual" of Hainan Cancer Hospital - 2017

II. "Most Collaborative Individual" of Hainan Cancer Hospital - 2019

III. “Excellent Staff” of the Group—— 2019

IV. The Most Beautiful Physician" of Hainan Cancer Hospital on Chinese Physicians Day - 2020

I. CircPDSS1 Promotes the Proliferation, Invasion, Migration, and EMT of Breast Cancer Cell via Regulating miR-320c/CKAP5 Axis. Cancer Cell Int. 2022 Jul 28;22(1):238.

II. RNA SOX21-AS1 Regulates the Progression of Triple-negative Breast Cancer through Regulation of miR-520a-5p/ORMDL3 Axis.J Cell Biochem. 2020;10.1002/jcb.29674.

III. Effectiveness of Prophylactic Application of Negative Pressure Wound Therapy in Stopping Surgical Site Wound Problems for Closed Incisions in Breast Cancer Surgery: A Meta-analysis. Int Wound J. 2023 Feb;20(2):241-250.

IV. Superselective Arterial Embolization with Drug-loaded Microspheres for the Treatment of Unresectable Breast Cancer.Gland Surg. 2019;8(6):740-747.

V. Construction of Lentiviral Expression Vectors for Tandem Affinity-tagged LOX Protein and It Expression in Breast Cancer Cells. Progress in Modern Biomedicine, 2015,15(29):5613-5616.

VI. Validation of the Interaction between LOX and XRCC5 in Human Breast Cancer Cells with Immunoprecipitation Technique. Journal of Guangxi Medical University, 2016, 33(01): 6-9.

VII. Application of Tandem Affinity Purification Techniques in the Study of Intracellularly Interacting Proteins. Medical Review, 2014, 20(7):1153-1156.